If you or a loved one suffered a serious injury like kidney failure, heart attack, stroke, or ketoacidosis while taking Invokana to treat type 2 diabe...
In March 2013, the Food and Drug Administration (FDA) approved the sale and marketing of Invokana (canaglifozin). Invokana is in a class of drugs know...
In March 2013, after analyzing only one year’s worth of data detailing the side effects of Invokana (canafligozan), the Food and Drug administration a...
Before the FDA approved Invokana in 2013, concerns were raised about the diabetes drug’s potential to cause heart problems. In January 2013, a review ...
Diabetic Ketoacidosis (DKA) is a severe condition that can lead to a diabetic coma or, in severe cases, death. DKA results from a shortage of insulin,...
European and Canadian health agencies have recently initiated safety reviews for Invokana and other sodium-glucose cotransporter-2 (SGLT2) inhibitors ...